{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14","upperLimit":"76","value":"48"},{"groupId":"OG001","lowerLimit":"4","upperLimit":"54","value":"25"},{"groupId":"OG002","lowerLimit":"2","upperLimit":"39","value":"15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"description":"Overall survival was defined as the time from the first dose date to date of death (any cause). Participants who were alive were censored at the last known time that the participant was alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Ewing's sarcoma: nab-paclitaxel at the RP2D (240 mg/m\\^2 in participants weighing \\> 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.","id":"OG000","title":"Phase 2: Ewing's Sarcoma"},{"description":"Participants with neuroblastoma: nab-paclitaxel at the RP2D (240 mg/m\\^2 in participants weighing \\> 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.","id":"OG001","title":"Phase 2: Neuroblastoma"},{"description":"Participants with rhabdomyosarcoma: nab-paclitaxel at the RP2D (240 mg/m\\^2 in participants weighing \\> 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.","id":"OG002","title":"Phase 2: Rhabdomyosarcoma"}],"paramType":"NUMBER","populationDescription":"Efficacy Evaluable Population: participants who met eligibility criteria for Phase 2, completed ≥1 dose of study drug, and had baseline and ≥1 postbaseline efficacy assessment if having not discontinued the investigational product prior to postbaseline efficacy assessment due to disease progression or systematic deterioration.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Phase 2: Kaplan-Meier Estimate of Overall Survival Rate at 1 Year","type":"SECONDARY","unitOfMeasure":"percentage of participants"}